Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:benzodioxine
go back to main search page
Accession:CHEBI:64096 term browser browse the term
Definition:Any organic heterobicyclic compound containing ortho-fused benzene and dioxine rings.
Synonyms:related_synonym: benzodioxines


show annotations for term's descendants           Sort by:
 
2-methoxyidazoxan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adra2a adrenoceptor alpha 2A affects binding
multiple interactions
ISO ADRA2A protein binds to 2-methoxyidazoxan
Epinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]; Norepinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]; Oxymetazoline inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]; xylometazoline inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]
CTD PMID:20030735 NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
JBrowse link
G Adra2b adrenoceptor alpha 2B affects binding
multiple interactions
ISO ADRA2B protein binds to 2-methoxyidazoxan
Epinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]; Norepinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]; Oxymetazoline inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]; xylometazoline inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]
CTD PMID:20030735 NCBI chr 3:119,805,941...119,809,987
Ensembl chr 3:119,805,941...119,809,987
JBrowse link
G Adra2c adrenoceptor alpha 2C multiple interactions
affects binding
affects response to substance
ISO Epinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]; Norepinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]; Oxymetazoline inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]; xylometazoline inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]
ADRA2C affects the susceptibility to 2-methoxyidazoxan
CTD PMID:10336518, PMID:20030735 NCBI chr14:80,730,307...80,732,010
Ensembl chr14:80,730,307...80,732,010
JBrowse link
G Ccnd1 cyclin D1 multiple interactions EXP 2-methoxyidazoxan inhibits the reaction [Epinephrine results in increased expression of CCND1 protein] CTD PMID:17680988 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
doxazosin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO Doxazosin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin] CTD PMID:11895100 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Adra1a adrenoceptor alpha 1A affects binding EXP
ISO
Doxazosin binds to ADRA1A protein CTD PMID:7536677, PMID:8183249, PMID:21544540 NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
JBrowse link
G Adra1b adrenoceptor alpha 1B affects binding ISO Doxazosin binds to ADRA1B protein CTD PMID:8183249 NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
JBrowse link
G Adra1d adrenoceptor alpha 1D affects binding ISO
EXP
Doxazosin binds to ADRA1D protein CTD PMID:8183249, PMID:9294627 NCBI chr 3:124,129,558...124,145,566
Ensembl chr 3:124,129,558...124,145,566
JBrowse link
G Adra2a adrenoceptor alpha 2A multiple interactions
decreases expression
increases activity
ISO Doxazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]
Doxazosin results in decreased expression of ADRA2A protein
Doxazosin results in increased activity of ADRA2A protein
CTD PMID:10694191, PMID:10742289 NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
JBrowse link
G Adrb1 adrenoceptor beta 1 increases expression EXP Doxazosin results in increased expression of ADRB1 protein CTD PMID:18084315 NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
JBrowse link
G Adrb2 adrenoceptor beta 2 increases expression EXP Doxazosin results in increased expression of ADRB2 protein CTD PMID:18084315 NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
JBrowse link
G Akt1 AKT serine/threonine kinase 1 affects phosphorylation EXP Doxazosin affects the phosphorylation of AKT1 protein CTD PMID:18084315 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions
ISO Doxazosin results in increased expression of BAX protein
SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of BAX protein]
CTD PMID:16007219 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO BCL2 inhibits the reaction [Doxazosin results in decreased expression of VEGFA] CTD PMID:12576871 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions
ISO Doxazosin results in increased activity of CASP3 protein
Doxazosin results in increased cleavage of and results in increased activity of CASP3 protein
CTD PMID:12771931, PMID:15221243, PMID:22845314 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccna2 cyclin A2 decreases expression ISO Doxazosin results in decreased expression of CCNA2 protein CTD PMID:15371785 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO Doxazosin results in increased expression of CDKN1A mRNA CTD PMID:12771931 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions EXP Doxazosin inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA] CTD PMID:19575289 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Crp C-reactive protein decreases expression ISO Doxazosin results in decreased expression of CRP protein CTD PMID:16680063 NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO Doxazosin results in increased expression of DDIT3 protein CTD PMID:22845314 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Epha2 Eph receptor A2 multiple interactions ISO [Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein] which results in increased phosphorylation of and results in increased activity of PTPN11 protein; Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein; Lithocholic Acid inhibits the reaction [Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein] CTD PMID:22845314 NCBI chr 5:159,845,773...159,874,203
Ensembl chr 5:159,845,774...159,874,206
JBrowse link
G Faslg Fas ligand increases expression ISO Doxazosin results in increased expression of FASLG mRNA CTD PMID:12771931 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Klf10 Kruppel-like factor 10 increases expression ISO Doxazosin results in increased expression of KLF10 mRNA; Doxazosin results in increased expression of KLF10 protein CTD PMID:12771931 NCBI chr 7:77,156,010...77,162,096
Ensembl chr 7:77,156,006...77,162,148
JBrowse link
G Mapk1 mitogen activated protein kinase 1 affects phosphorylation EXP Doxazosin affects the phosphorylation of MAPK1 protein CTD PMID:18084315 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 affects phosphorylation EXP Doxazosin affects the phosphorylation of MAPK3 protein CTD PMID:18084315 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mstn myostatin decreases expression EXP Doxazosin results in decreased expression of MSTN mRNA; Doxazosin results in decreased expression of MSTN protein CTD PMID:16968467 NCBI chr 9:53,310,977...53,315,804
Ensembl chr 9:53,309,598...53,315,915
JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression ISO Doxazosin results in increased expression of NFKBIA mRNA; Doxazosin results in increased expression of NFKBIA protein CTD PMID:12771931 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nppb natriuretic peptide B increases expression
multiple interactions
ISO
EXP
Doxazosin results in increased expression of NPPB protein
[Atenolol co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Atenolol co-treated with Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA
CTD PMID:15969258, PMID:18551024 NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
JBrowse link
G Ptk2 protein tyrosine kinase 2 decreases expression
increases cleavage
ISO Doxazosin results in decreased expression of PTK2 protein
Doxazosin results in increased cleavage of PTK2 protein
CTD PMID:15221243, PMID:22845314 NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
JBrowse link
G Ptpn11 protein tyrosine phosphatase, non-receptor type 11 multiple interactions ISO [Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein] which results in increased phosphorylation of and results in increased activity of PTPN11 protein CTD PMID:22845314 NCBI chr12:40,895,515...40,955,999
Ensembl chr12:40,895,515...40,955,999
JBrowse link
G Rb1 RB transcriptional corepressor 1 affects phosphorylation
decreases phosphorylation
EXP
ISO
Doxazosin affects the phosphorylation of RB1 protein
Doxazosin results in decreased phosphorylation of RB1 protein
CTD PMID:15371785, PMID:18084315 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Ren renin increases expression ISO Doxazosin results in increased expression of REN protein CTD PMID:7818152 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
JBrowse link
G Serpinb5 serpin family B member 5 multiple interactions
increases response to substance
ISO SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA mRNA alternative form]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA protein]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of BAX protein]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 mRNA]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 protein]
SERPINB5 protein results in increased susceptibility to Doxazosin
CTD PMID:16007219 NCBI chr13:26,903,052...26,923,250
Ensembl chr13:26,903,052...26,923,250
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Doxazosin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
JBrowse link
G Smad4 SMAD family member 4 increases expression
multiple interactions
ISO Doxazosin results in increased expression of SMAD4 mRNA; Doxazosin results in increased expression of SMAD4 protein
SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 mRNA]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 protein]
CTD PMID:12771931, PMID:16007219 NCBI chr18:69,626,682...69,657,373
Ensembl chr18:69,627,757...69,671,199
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression
ISO BCL2 inhibits the reaction [Doxazosin results in decreased expression of VEGFA]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA mRNA alternative form]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA protein]
Doxazosin results in decreased expression of VEGFA mRNA; Doxazosin results in decreased expression of VEGFA mRNA alternative form; Doxazosin results in decreased expression of VEGFA protein
CTD PMID:12576871, PMID:16007219 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
eliglustat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gba glucosylceramidase beta multiple interactions ISO eliglustat results in decreased activity of and affects the localization of GBA protein CTD PMID:21250698 NCBI chr 2:188,511,781...188,522,602
Ensembl chr 2:188,516,582...188,522,601
JBrowse link
idazoxan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adra2a adrenoceptor alpha 2A multiple interactions EXP [Idazoxan binds to and results in decreased activity of ADRA2A protein] which results in decreased susceptibility to amitraz CTD PMID:10582558 NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
JBrowse link
G Adrb1 adrenoceptor beta 1 multiple interactions EXP [Imipramine co-treated with Idazoxan] results in decreased activity of ADRB1 protein CTD PMID:2868116 NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
JBrowse link
G Crh corticotropin releasing hormone decreases expression EXP Idazoxan results in decreased expression of CRH mRNA CTD PMID:1351783 NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO Idazoxan inhibits the reaction [Bee Venoms promotes the reaction [Methamphetamine results in increased expression of FOS protein]] CTD PMID:20950675 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Gad2 glutamate decarboxylase 2 multiple interactions EXP [methylhistaprodifen co-treated with Idazoxan] inhibits the reaction [amitraz affects the expression of GAD2 mRNA]; Idazoxan inhibits the reaction [amitraz affects the expression of GAD2 mRNA] CTD PMID:26141220 NCBI chr17:89,171,576...89,234,770
Ensembl chr17:89,171,250...89,238,040
JBrowse link
G Gh1 growth hormone 1 decreases expression EXP Idazoxan results in decreased expression of GH1 protein CTD PMID:6150737 NCBI chr10:94,486,204...94,488,181
Ensembl chr10:94,486,205...94,488,180
JBrowse link
G Gls glutaminase multiple interactions EXP [methylhistaprodifen co-treated with Idazoxan] inhibits the reaction [amitraz results in increased expression of GLS mRNA] CTD PMID:26141220 NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases expression EXP Idazoxan results in increased expression of NR3C1 mRNA CTD PMID:1351783 NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
JBrowse link
G Prl prolactin decreases secretion EXP Idazoxan results in decreased secretion of PRL protein CTD PMID:1678730 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
JBrowse link
G Taar1 trace-amine-associated receptor 1 multiple interactions
increases activity
ISO [Idazoxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP CTD PMID:19725810 NCBI chr 1:22,595,477...22,596,475
Ensembl chr 1:22,595,477...22,596,475
JBrowse link
G Th tyrosine hydroxylase increases expression EXP Idazoxan results in increased expression of TH mRNA CTD PMID:1351783 NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
JBrowse link
silibinin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions EXP Silybin affects the localization of and affects the activity of ABCB11 protein CTD PMID:15763547 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Acaca acetyl-CoA carboxylase alpha multiple interactions
increases phosphorylation
ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased phosphorylation of ACACA protein]
Silybin results in increased phosphorylation of ACACA protein
CTD PMID:25294820, PMID:25559859 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Acly ATP citrate lyase decreases phosphorylation ISO Silybin results in decreased phosphorylation of ACLY protein CTD PMID:25294820 NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
JBrowse link
G Adipor2 adiponectin receptor 2 increases expression EXP silymarin (silibinin) increases expression of adipor2 mRNA and protein in epididymal white adipose tissue of alcohol fed rats RGD PMID:26115886 RGD:25330099 NCBI chr 4:151,412,135...151,480,108
Ensembl chr 4:151,414,684...151,428,894
JBrowse link
G Agpat3 1-acylglycerol-3-phosphate O-acyltransferase 3 multiple interactions EXP Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA] CTD PMID:28619387 NCBI chr20:11,060,584...11,144,806
Ensembl chr20:11,114,164...11,144,806
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 decreases activity ISO Silybin results in decreased activity of AKR1C3 protein CTD PMID:19007764 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of AKT1 protein] CTD PMID:25559859 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Amacr alpha-methylacyl-CoA racemase decreases expression ISO Silybin results in decreased expression of AMACR protein CTD PMID:25294820 NCBI chr 2:60,949,276...60,961,342
Ensembl chr 2:60,949,256...60,961,326
JBrowse link
G Apoa5 apolipoprotein A5 multiple interactions EXP Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA] CTD PMID:28619387 NCBI chr 8:50,559,079...50,561,720
Ensembl chr 8:50,559,126...50,561,736
JBrowse link
G Asl argininosuccinate lyase multiple interactions EXP Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein] CTD PMID:28619387 NCBI chr12:30,160,922...30,178,348
Ensembl chr12:30,165,694...30,178,341
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO Silybin results in increased phosphorylation of and results in increased activity of ATM protein CTD PMID:16777994 NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO Silybin inhibits the reaction [Mitomycin affects the localization of BAX protein] CTD PMID:19834285 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions
ISO Silybin results in decreased expression of BCL2 mRNA
[Silybin co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; Silybin inhibits the reaction [Mitomycin affects the expression of BCL2]
CTD PMID:19834285, PMID:21969006 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions
increases cleavage
affects localization
ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of BID protein]; Caffeine inhibits the reaction [Silybin results in increased cleavage of BID protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of BID protein]
Silybin affects the localization of BID protein modified form
CTD PMID:16777994 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [Silybin co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA CTD PMID:21969006 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Ca9 carbonic anhydrase 9 decreases expression
multiple interactions
ISO Silybin results in decreased expression of CA9 mRNA
Arsenic Trioxide promotes the reaction [Silybin results in decreased expression of CA9 mRNA]
CTD PMID:21969006 NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
JBrowse link
G Casp2 caspase 2 multiple interactions ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP2 protein]; Caffeine inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP2 protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP2 protein]; Silybin results in increased cleavage of and results in increased activity of CASP2 protein CTD PMID:16777994 NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
JBrowse link
G Casp3 caspase 3 increases expression
multiple interactions
increases activity
ISO Silybin results in increased expression of CASP3 mRNA
Arsenic Trioxide promotes the reaction [Silybin results in increased activity of CASP3 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP3 protein]; Caffeine inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP3 protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP3 protein]; Silybin promotes the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; Silybin results in increased cleavage of and results in increased activity of CASP3 protein
CTD PMID:16777994, PMID:21969006 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP8 protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP8 protein]; Silybin results in increased cleavage of and results in increased activity of CASP8 protein CTD PMID:16777994 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP9 protein]; Caffeine inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP9 protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP9 protein]; Silybin results in increased cleavage of and results in increased activity of CASP9 protein CTD PMID:16777994 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase multiple interactions EXP Silybin inhibits the reaction [Arsenic results in decreased activity of CAT protein]; Silybin inhibits the reaction [sodium arsenite results in decreased expression of CAT] CTD PMID:22229868, PMID:23070905 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccna2 cyclin A2 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCNA2 protein] CTD PMID:25559859 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO Silybin inhibits the reaction [Arsenic results in increased expression of CCNB1] CTD PMID:25868784 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCND1 protein]
Silybin results in decreased expression of CCND1 protein
[Silybin co-treated with Arsenic] results in decreased expression of CCND1 protein
CTD PMID:16788158, PMID:25559859, PMID:25868784 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd3 cyclin D3 multiple interactions ISO [Silybin co-treated with Arsenic] results in decreased expression of CCND3 protein CTD PMID:25868784 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions ISO Silybin inhibits the reaction [Arsenic results in increased expression of CDK1 protein] CTD PMID:25868784 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions ISO [Silybin co-treated with Arsenic] results in decreased expression of CDK2 protein CTD PMID:25868784 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions ISO [Silybin co-treated with Arsenic] results in decreased expression of CDK4 protein CTD PMID:25868784 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions ISO [Silybin co-treated with Arsenic] results in decreased expression of CDK6 protein CTD PMID:25868784 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases cleavage
ISO [Silybin co-treated with Arsenic] results in increased expression of CDKN1A protein; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of CDKN1A protein] CTD PMID:16777994, PMID:25868784 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CDKN1B protein]
[Silybin co-treated with Arsenic] results in increased expression of CDKN1B protein
CTD PMID:25559859, PMID:25868784 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein] CTD PMID:25559859 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Chek2 checkpoint kinase 2 increases phosphorylation
multiple interactions
ISO Silybin results in increased phosphorylation of CHEK2 protein
Caffeine inhibits the reaction [Silybin results in increased phosphorylation of CHEK2 protein]
CTD PMID:16777994 NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions EXP [Silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA] CTD PMID:16169303 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Ctsb cathepsin B multiple interactions ISO [Arsenic Trioxide co-treated with Silybin] results in decreased expression of CTSB mRNA CTD PMID:21969006 NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
JBrowse link
G Cyb5a cytochrome b5 type A multiple interactions EXP Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA] CTD PMID:28619387 NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions EXP Silybin inhibits the reaction [sodium arsenite results in increased expression of CYBB] CTD PMID:24062023 NCBI chr  X:14,578,330...14,610,049
Ensembl chr  X:14,578,264...14,612,547
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases activity ISO Silybin results in decreased activity of CYP2C8 protein CTD PMID:28457856 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO DDIT3 affects the reaction [Silybin results in increased expression of TNFRSF10B] CTD PMID:19939880 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dlk1 delta like non-canonical Notch ligand 1 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of DLK1 mRNA] CTD PMID:25559859 NCBI chr 6:133,576,513...133,583,751
Ensembl chr 6:133,552,821...133,583,751
JBrowse link
G Egr1 early growth response 1 increases expression
multiple interactions
ISO Silybin results in increased expression of EGR1 protein
EGR1 mutant form inhibits the reaction [Silybin results in increased expression of GDF15 protein]
CTD PMID:24440808 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions EXP
ISO
Silybin results in increased activity of [ESR1 protein binds to ESR2 protein] CTD PMID:16076518 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO
EXP
Silybin results in increased activity of [ESR1 protein binds to ESR2 protein] CTD PMID:16076518 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 protein] CTD PMID:25559859 NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
JBrowse link
G Fasn fatty acid synthase multiple interactions
decreases expression
ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FASN protein]
Silybin results in decreased expression of FASN protein
CTD PMID:25294820, PMID:25559859 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions ISO Silybin inhibits the reaction [Urethane results in increased secretion of FGF2 protein] CTD PMID:16788158 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase multiple interactions EXP Silybin inhibits the reaction [Arsenic results in decreased activity of G6PD protein] CTD PMID:22229868 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Gdf15 growth differentiation factor 15 increases expression
multiple interactions
ISO Silybin results in increased expression of GDF15 mRNA; Silybin results in increased expression of GDF15 protein
EGR1 mutant form inhibits the reaction [Silybin results in increased expression of GDF15 protein]; GDF15 mutant form inhibits the reaction [Silybin results in increased cleavage of PARP1 protein]; pyrazolanthrone promotes the reaction [Silybin results in increased expression of GDF15 protein]; SB 203580 inhibits the reaction [Silybin results in increased expression of GDF15 protein]
CTD PMID:24440808 NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP Silybin inhibits the reaction [Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]] CTD PMID:28619387 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP Silybin inhibits the reaction [Arsenic results in decreased activity of GSR protein] CTD PMID:22229868 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases phosphorylation
ISO Caffeine inhibits the reaction [Silybin results in increased phosphorylation of H2AX protein] CTD PMID:16777994 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase decreases expression ISO Silybin results in decreased expression of HMGCR protein CTD PMID:25294820 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP Silybin inhibits the reaction [sodium arsenite results in decreased expression of HMOX1] CTD PMID:24062023 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions EXP Silybin inhibits the reaction [sodium arsenite results in increased expression of KEAP1] CTD PMID:24062023 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Klf2 Kruppel-like factor 2 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of KLF2 mRNA] CTD PMID:25559859 NCBI chr16:19,223,087...19,225,037
Ensembl chr16:19,223,087...19,225,037
JBrowse link
G Klf4 Kruppel like factor 4 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of KLF4 mRNA] CTD PMID:25559859 NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
JBrowse link
G Klf5 Kruppel-like factor 5 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of KLF5 mRNA] CTD PMID:25559859 NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
JBrowse link
G Lpin1 lipin 1 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of LPIN1 protein] CTD PMID:25559859 NCBI chr 6:41,796,214...41,905,149
Ensembl chr 6:41,799,749...41,870,046
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of MAPK1 protein] CTD PMID:25559859 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of MAPK3 protein] CTD PMID:25559859 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions
ISO Silybin results in increased phosphorylation of MAPK8 protein
pifithrin inhibits the reaction [Silybin results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Silybin results in increased phosphorylation of MAPK8 protein]
CTD PMID:16777994 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions
increases phosphorylation
ISO pifithrin inhibits the reaction [Silybin results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Silybin results in increased phosphorylation of MAPK9 protein] CTD PMID:16777994 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase multiple interactions ISO Silybin results in increased expression of and results in increased activity of MGMT protein CTD PMID:16950796 NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
JBrowse link
G Mmp14 matrix metallopeptidase 14 multiple interactions ISO [Arsenic Trioxide co-treated with Silybin] results in decreased expression of MMP14 mRNA; Arsenic Trioxide inhibits the reaction [Silybin results in increased expression of MMP14 mRNA] CTD PMID:21969006 NCBI chr15:33,074,441...33,083,666
Ensembl chr15:33,074,441...33,083,655
JBrowse link
G Mmp2 matrix metallopeptidase 2 increases expression
multiple interactions
ISO
EXP
Silybin results in increased expression of MMP2 mRNA
[Silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA]
[Arsenic Trioxide co-treated with Silybin] results in decreased activity of MMP2 protein; [Arsenic Trioxide co-treated with Silybin] results in decreased expression of MMP2 mRNA; [Silybin co-treated with Arsenic] results in decreased expression of MMP2; Silybin promotes the reaction [Arsenic Trioxide results in decreased expression of MMP2 mRNA]
CTD PMID:16169303, PMID:21969006, PMID:25868784 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp9 matrix metallopeptidase 9 decreases expression
multiple interactions
decreases activity
ISO Silybin results in decreased expression of MMP9 mRNA
[Arsenic Trioxide co-treated with Silybin] results in decreased expression of MMP9 mRNA; [Silybin co-treated with Arsenic Trioxide] results in decreased activity of MMP9 protein
Silybin results in decreased activity of MMP9 protein
CTD PMID:21969006 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO Silybin results in decreased expression of MYC protein CTD PMID:27746612 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nat2 N-acetyltransferase 2 multiple interactions EXP Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA] CTD PMID:28619387 NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP Silybin inhibits the reaction [sodium arsenite results in decreased expression of NFE2L2] CTD PMID:24062023 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
decreases expression
EXP
ISO
Silybin inhibits the reaction [sodium arsenite results in increased expression of NOS2]
Silybin results in decreased expression of NOS2 protein
CTD PMID:16788158, PMID:23070905 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions EXP Silybin inhibits the reaction [sodium arsenite results in increased expression of NOX4] CTD PMID:24062023 NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 decreases expression IEP Silymarin decreases Nqo1 mRNA in liver RGD PMID:31432116 RGD:25823187 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases expression EXP silymarin increases Nr1h4 mRNA expression in rat kidney and liver RGD PMID:30308196 RGD:15042865 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression ISO Silybin results in increased expression of NR1I2 mRNA CTD PMID:29933105 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
ISO Silybin results in increased cleavage of PARP1 protein
benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Silybin results in increased cleavage of PARP1 protein]; GDF15 mutant form inhibits the reaction [Silybin results in increased cleavage of PARP1 protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of PARP1 protein]; Silybin results in increased cleavage of and results in increased activity of PARP1 protein
CTD PMID:16777994, PMID:24440808 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pcna proliferating cell nuclear antigen decreases expression ISO Silybin results in decreased expression of PCNA protein CTD PMID:16788158 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 decreases expression ISO Silybin results in decreased expression of PECAM1 protein CTD PMID:16788158 NCBI chr10:94,850,971...94,913,202 JBrowse link
G Plau plasminogen activator, urokinase multiple interactions
decreases expression
ISO [Silybin co-treated with Arsenic Trioxide] results in decreased expression of PLAU mRNA; Arsenic Trioxide promotes the reaction [Silybin results in decreased expression of PLAU mRNA]; Silybin promotes the reaction [Arsenic Trioxide results in decreased expression of PLAU mRNA] CTD PMID:21969006 NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
JBrowse link
G Por cytochrome p450 oxidoreductase multiple interactions EXP Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA] CTD PMID:28619387 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein]
Silybin results in increased expression of PPARG protein
CTD PMID:25559859, PMID:27746612 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases expression ISO Silybin results in decreased expression of PTGS2 protein CTD PMID:16788158 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of RB1 protein] CTD PMID:25559859 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Slc16a1 solute carrier family 16 member 1 multiple interactions ISO Silybin inhibits the reaction [SLC16A1 protein results in increased uptake of Benzoic Acid] CTD PMID:17976262 NCBI chr 2:207,108,552...207,129,352
Ensembl chr 2:207,108,552...207,128,554
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions ISO Silybin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein] CTD PMID:18591783 NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions
decreases response to substance
ISO fatostatin promotes the reaction [Silybin results in decreased cleavage of SREBF1 protein]; Silybin results in decreased cleavage of and results in increased phosphorylation of SREBF1 protein
SREBF1 protein results in decreased susceptibility to Silybin
CTD PMID:25294820 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP [Silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA] CTD PMID:16169303 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions EXP [Silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA] CTD PMID:16169303 NCBI chr  X:1,364,771...1,369,451
Ensembl chr  X:1,364,786...1,369,384
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein] CTD PMID:28619387 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 multiple interactions
affects localization
increases phosphorylation
increases expression
ISO Caffeine inhibits the reaction [Silybin results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Silybin results in increased phosphorylation of TP53 protein]; Silybin inhibits the reaction [Mitomycin results in increased expression of TP53]
Silybin affects the localization of TP53 protein
Silybin results in increased expression of TP53 protein
CTD PMID:16777994, PMID:19834285 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 decreases activity
multiple interactions
EXP
ISO
Silybin metabolite results in decreased activity of UGT1A1 protein
Silybin inhibits the reaction [UGT1A1 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin]
CTD PMID:15155549, PMID:15921999 NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt1a6 UDP glucuronosyltransferase family 1 member A6 multiple interactions
decreases activity
ISO
EXP
Silybin inhibits the reaction [UGT1A6 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin]
Silybin metabolite results in decreased activity of UGT1A6 protein
CTD PMID:15155549, PMID:15921999 NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt1a9 UDP glucuronosyltransferase family 1 member A9 multiple interactions ISO Silybin inhibits the reaction [UGT1A9 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] CTD PMID:15155549 NCBI chr 9:95,161,157...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 multiple interactions ISO Silybin inhibits the reaction [UGT2B7 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] CTD PMID:15155549 NCBI chr14:22,597,103...22,619,968 JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression
ISO Silybin promotes the reaction [Lipids deficiency inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein]]; Silybin promotes the reaction [Lipids deficiency results in decreased expression of VEGFA protein]
Silybin results in decreased expression of VEGFA protein
Silybin inhibits the reaction [Urethane results in increased secretion of VEGFA protein]
CTD PMID:16788158, PMID:26087400 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vim vimentin multiple interactions ISO [Silybin co-treated with Arsenic] results in decreased expression of VIM CTD PMID:25868784 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    chemical entity 19785
      atom 19782
        nonmetal atom 19657
          oxygen atom 19321
            oxygen molecular entity 19321
              organooxygen compound 18777
                oxacycle 17181
                  benzodioxine 127
                    (4-Methoxyphenyl)-(2-methylsulfanyl-6,7-dihydro-[1,4]dioxino[2,3-f]benzimidazol-3-yl)methanone 0
                    1-(1,3-benzodioxol-5-yl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)urea 0
                    1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-piperidinecarboxamide 0
                    1-(2,3-Dihydro-1,4-benzodioxin-3-ylmethyl)-5-ethoxy-isatin 0
                    1-(2,3-Dihydro-1,4-benzodioxin-3-ylmethyl)-5-methoxy-isatin 0
                    1-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-[3-(dimethylamino)propyl]-1-ethylthiourea 0
                    1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(4,6-dimethyl-2-pyrimidinyl)guanidine 0
                    1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-([1,2,4]triazolo[4,3-a]pyridin-3-ylthio)ethanone 0
                    1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(1-propan-2-yl-5-tetrazolyl)thio]ethanone 0
                    1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[4-(2-phenylethenyl)-1-pyridin-1-iumyl]ethanone 0
                    1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[5-(3,5-dimethylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone 0
                    1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-hydroxy-3-pyrazolecarboxylic acid ethyl ester 0
                    1-(2,3-dihydro-1,4-benzodioxin-6-ylmethylideneamino)-3-(2-methoxyethyl)thiourea 0
                    1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(2-furanylsulfonyl)piperazine 0
                    1-[1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-piperidinyl]-5-fluorobenzotriazole 0
                    1-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-3,4-dioxo-1-cyclobutenyl]-4-piperidinecarboxylic acid ethyl ester 0
                    1-acetyl-5-bromo-N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-2-methyl-2,3-dihydroindole-7-sulfonamide 0
                    1-cyclohexyl-3-(2,3-dihydro-1,4-benzodioxin-6-yl)urea 0
                    2,3-dihydro-1,4-benzodioxin-6-carboxylic acid [2-(2,5-dichloroanilino)-2-oxoethyl] ester 0
                    2,3-dihydro-1,4-benzodioxine-6-carbaldehyde 0
                    2,4-dibromo-6-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)methylidene]-1-cyclohexa-2,4-dienone 0
                    2-(1H-benzimidazol-2-ylthio)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide 0
                    2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-ethylimidazole 0
                    2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(3-ethylphenyl)-3-hydroxy-5-nitro-4-triazolimine 0
                    2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-4,6-dimethyl-3-pyridinecarbonitrile 0
                    2-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-oxomethyl]-1-cyclohexanecarboxylic acid 0
                    2-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]-1,1-dioxo-1,2-benzothiazol-3-one 0
                    2-[[2,3-dihydro-1,4-benzodioxin-3-yl(oxo)methyl]amino]-6-methyl-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxamide 0
                    2-[[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide 0
                    2-methoxyidazoxan 4
                    3-(2,3-dihydro-1,4-benzodioxin-3-yl)-6-(4-fluorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 0
                    3-(2,3-dihydro-1,4-benzodioxin-3-yl)-N-(3-hydroxy-2-pyridinyl)propanamide 0
                    3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-6-(phenylmethyl)-2H-1,2,4-triazin-5-one 0
                    3-chloro-N-(2,3-dihydro-1,4-benzodioxin-6-ylmethylideneamino)-4-methylaniline 0
                    3-tert-butyl-7-[[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]thio]-[1,3,4]thiadiazolo[2,3-c][1,2,4]triazin-4-one 0
                    4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-thiazolamine 0
                    4-(2,6-difluorophenyl)sulfonyl-1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperidine 0
                    4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-sulfanylidene-1,2,4-triazolidin-3-ylidene]-3-hydroxy-1-cyclohexa-2,5-dienone 0
                    4-[[[5-(2,3-dihydro-1,4-benzodioxin-3-yl)-4-prop-2-enyl-1,2,4-triazol-3-yl]thio]methyl]-3,5-dimethylisoxazole 0
                    4-amino-2-[[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]thio]-5-pyrimidinecarboxylic acid ethyl ester 0
                    4-chloro-5-(2,3-dihydro-1,4-benzodioxin-3-yl)thieno[2,3-d]pyrimidine 0
                    4-methyl-2-oxochromen-7-yl \{[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methyl-4-oxochromen-7-yl]oxy\}acetate 0
                    5''-methoxyhydnocarpin-D 0
                    5-[[[5-(2,3-dihydro-1,4-benzodioxin-3-yl)-4-methyl-1,2,4-triazol-3-yl]thio]methyl]-2-phenylthiazole 0
                    5-methoxy-3-methyl-2-benzofurancarboxylic acid [2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl] ester 0
                    6-(2,3-dihydro-1,4-benzodioxin-3-yl)-3-(phenoxymethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 0
                    6-[4-(2,6-difluorophenyl)sulfonylcyclohexyl]sulfonyl-2,3-dihydro-1,4-benzodioxin 0
                    6-chloro-2-[1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-piperidinyl]-1H-benzimidazole 0
                    6-tert-butyl-N'-(2-pyrrolylidenemethyl)-2,3-dihydro-1,4-benzodioxin-3-carbohydrazide 0
                    6-tert-butyl-N-(2-pyridinylmethylideneamino)-2,3-dihydro-1,4-benzodioxin-3-carboxamide 0
                    6-tert-butyl-N-(pyridin-4-ylmethylideneamino)-2,3-dihydro-1,4-benzodioxin-3-carboxamide 0
                    6-tert-butyl-N-[(1-methyl-2-pyrrolyl)methylideneamino]-2,3-dihydro-1,4-benzodioxin-3-carboxamide 0
                    CCT-018159 0
                    LSM-32717 0
                    N'-(2,3-dihydro-1,4-benzodioxin-6-ylmethylideneamino)-N-(2-hydroxyphenyl)octanediamide 0
                    N'-(2-pyrrolylidenemethyl)-2,3-dihydro-1,4-benzodioxin-3-carbohydrazide 0
                    N'-[(5-nitro-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]-2,3-dihydro-1,4-benzodioxin-3-carbohydrazide 0
                    N-(1,3-benzodioxol-5-ylmethylideneamino)-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine 0
                    N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-2-(6-methoxy-3-benzofuranyl)-N-methylacetamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-5,6-dimethyl-4-thieno[2,3-d]pyrimidinamine 0
                    N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-5-ethyl-2-furancarboxamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,5-dimethyl-4-pyrazolecarboxamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-(2-pyrimidinyl)-3-piperidinecarboxamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(6-methoxy-1H-benzimidazol-2-yl)thio]acetamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[4-(2-furanylmethyl)-5-(phenoxymethyl)-1,2,4-triazol-3-yl]thio]acetamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methoxy-4-propan-2-yloxybenzamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-morpholinecarboxamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5,7-dimethyl-3-pyrazolo[1,5-a]pyrimidinecarboxamide 0
                    N-(3-chloro-2-pyridinyl)-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                    N-(3-methyl-6-methylsulfonyl-1,3-benzothiazol-2-ylidene)-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                    N-(4-bromo-1,3-benzothiazol-2-yl)-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                    N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-oxo-3-pyrrolidinecarboxamide 0
                    N-(6-bromo-2,3-dihydro-1,4-benzodioxin-7-yl)-2-furancarboxamide 0
                    N-(6-chloro-2,3-dihydro-1,4-benzodioxin-7-yl)-3-phenylpropanamide 0
                    N-(6-fluoro-1,3-benzothiazol-2-yl)-6,7-dihydro-[1,4]dioxino[2,3-f][1,3]benzothiazol-2-amine 0
                    N-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-oxomethyl]-2-[[5-(2-methoxyanilino)-1,3,4-thiadiazol-2-yl]thio]acetamide 0
                    N-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-sulfanylidenemethyl]-2,4-dimethylbenzamide 0
                    N-[(2-chlorophenyl)methyl]-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-hydroxy-5-nitro-4-triazolimine 0
                    N-[(2-methoxyphenyl)methyl]-N-methyl-2,3-dihydro-1,4-benzodioxin-3-carboxamide 0
                    N-[(3-bromo-4-ethoxy-5-methoxyphenyl)methyl]-2,3-dihydro-1,4-benzodioxin-6-amine 0
                    N-[(4,5-dibromo-2-furanyl)methylideneamino]-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                    N-[(5-bromo-2-furanyl)methylideneamino]-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                    N-[(6-chloro-1,3-benzodioxol-5-yl)methylideneamino]-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                    N-[1-[4-(4-methylphenyl)-2-thiazolyl]-4-piperidinyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide 0
                    N-[2-(2-imidazo[1,2-a]pyridinyl)ethyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide 0
                    N-[7-(1-oxopropyl)-2,3-dihydro-1,4-benzodioxin-6-yl]benzamide 0
                    N-[[5-(2-nitrophenyl)-2-furanyl]methylideneamino]-2,3-dihydro-1,4-benzodioxin-3-carboxamide 0
                    aiphanol 0
                    doxazosin + 32
                    eliglustat 1
                    guabenxan 0
                    guaimesal 0
                    guanoxan 0
                    idazoxan + 14
                    lignin cw compound-3043 0
                    lignin cw compound-3044 0
                    lignin cw compound-3068 0
                    lignin cw compound-3069 0
                    lignin cw compound-3070 0
                    silandrin 0
                    silibinin 95
Path 2
Term Annotations click to browse term
  CHEBI ontology 19785
    subatomic particle 19782
      composite particle 19782
        hadron 19782
          baryon 19782
            nucleon 19782
              atomic nucleus 19782
                atom 19782
                  main group element atom 19670
                    p-block element atom 19670
                      carbon group element atom 19572
                        carbon atom 19561
                          organic molecular entity 19561
                            organic molecule 19486
                              organic cyclic compound 19282
                                organic heterocyclic compound 18407
                                  organic heteropolycyclic compound 17820
                                    organic heterobicyclic compound 16742
                                      benzodioxine 127
                                        (4-Methoxyphenyl)-(2-methylsulfanyl-6,7-dihydro-[1,4]dioxino[2,3-f]benzimidazol-3-yl)methanone 0
                                        1-(1,3-benzodioxol-5-yl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)urea 0
                                        1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-piperidinecarboxamide 0
                                        1-(2,3-Dihydro-1,4-benzodioxin-3-ylmethyl)-5-ethoxy-isatin 0
                                        1-(2,3-Dihydro-1,4-benzodioxin-3-ylmethyl)-5-methoxy-isatin 0
                                        1-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-[3-(dimethylamino)propyl]-1-ethylthiourea 0
                                        1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(4,6-dimethyl-2-pyrimidinyl)guanidine 0
                                        1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-([1,2,4]triazolo[4,3-a]pyridin-3-ylthio)ethanone 0
                                        1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(1-propan-2-yl-5-tetrazolyl)thio]ethanone 0
                                        1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[4-(2-phenylethenyl)-1-pyridin-1-iumyl]ethanone 0
                                        1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[5-(3,5-dimethylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone 0
                                        1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-hydroxy-3-pyrazolecarboxylic acid ethyl ester 0
                                        1-(2,3-dihydro-1,4-benzodioxin-6-ylmethylideneamino)-3-(2-methoxyethyl)thiourea 0
                                        1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(2-furanylsulfonyl)piperazine 0
                                        1-[1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-piperidinyl]-5-fluorobenzotriazole 0
                                        1-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-3,4-dioxo-1-cyclobutenyl]-4-piperidinecarboxylic acid ethyl ester 0
                                        1-acetyl-5-bromo-N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-2-methyl-2,3-dihydroindole-7-sulfonamide 0
                                        1-cyclohexyl-3-(2,3-dihydro-1,4-benzodioxin-6-yl)urea 0
                                        2,3-dihydro-1,4-benzodioxin-6-carboxylic acid [2-(2,5-dichloroanilino)-2-oxoethyl] ester 0
                                        2,3-dihydro-1,4-benzodioxine-6-carbaldehyde 0
                                        2,4-dibromo-6-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)methylidene]-1-cyclohexa-2,4-dienone 0
                                        2-(1H-benzimidazol-2-ylthio)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide 0
                                        2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-ethylimidazole 0
                                        2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(3-ethylphenyl)-3-hydroxy-5-nitro-4-triazolimine 0
                                        2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-4,6-dimethyl-3-pyridinecarbonitrile 0
                                        2-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-oxomethyl]-1-cyclohexanecarboxylic acid 0
                                        2-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]-1,1-dioxo-1,2-benzothiazol-3-one 0
                                        2-[[2,3-dihydro-1,4-benzodioxin-3-yl(oxo)methyl]amino]-6-methyl-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxamide 0
                                        2-[[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide 0
                                        2-methoxyidazoxan 4
                                        3-(2,3-dihydro-1,4-benzodioxin-3-yl)-6-(4-fluorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 0
                                        3-(2,3-dihydro-1,4-benzodioxin-3-yl)-N-(3-hydroxy-2-pyridinyl)propanamide 0
                                        3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-6-(phenylmethyl)-2H-1,2,4-triazin-5-one 0
                                        3-chloro-N-(2,3-dihydro-1,4-benzodioxin-6-ylmethylideneamino)-4-methylaniline 0
                                        3-tert-butyl-7-[[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]thio]-[1,3,4]thiadiazolo[2,3-c][1,2,4]triazin-4-one 0
                                        4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-thiazolamine 0
                                        4-(2,6-difluorophenyl)sulfonyl-1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperidine 0
                                        4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-sulfanylidene-1,2,4-triazolidin-3-ylidene]-3-hydroxy-1-cyclohexa-2,5-dienone 0
                                        4-[[[5-(2,3-dihydro-1,4-benzodioxin-3-yl)-4-prop-2-enyl-1,2,4-triazol-3-yl]thio]methyl]-3,5-dimethylisoxazole 0
                                        4-amino-2-[[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]thio]-5-pyrimidinecarboxylic acid ethyl ester 0
                                        4-chloro-5-(2,3-dihydro-1,4-benzodioxin-3-yl)thieno[2,3-d]pyrimidine 0
                                        4-methyl-2-oxochromen-7-yl \{[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methyl-4-oxochromen-7-yl]oxy\}acetate 0
                                        5''-methoxyhydnocarpin-D 0
                                        5-[[[5-(2,3-dihydro-1,4-benzodioxin-3-yl)-4-methyl-1,2,4-triazol-3-yl]thio]methyl]-2-phenylthiazole 0
                                        5-methoxy-3-methyl-2-benzofurancarboxylic acid [2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl] ester 0
                                        6-(2,3-dihydro-1,4-benzodioxin-3-yl)-3-(phenoxymethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole 0
                                        6-[4-(2,6-difluorophenyl)sulfonylcyclohexyl]sulfonyl-2,3-dihydro-1,4-benzodioxin 0
                                        6-chloro-2-[1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-piperidinyl]-1H-benzimidazole 0
                                        6-tert-butyl-N'-(2-pyrrolylidenemethyl)-2,3-dihydro-1,4-benzodioxin-3-carbohydrazide 0
                                        6-tert-butyl-N-(2-pyridinylmethylideneamino)-2,3-dihydro-1,4-benzodioxin-3-carboxamide 0
                                        6-tert-butyl-N-(pyridin-4-ylmethylideneamino)-2,3-dihydro-1,4-benzodioxin-3-carboxamide 0
                                        6-tert-butyl-N-[(1-methyl-2-pyrrolyl)methylideneamino]-2,3-dihydro-1,4-benzodioxin-3-carboxamide 0
                                        CCT-018159 0
                                        LSM-32717 0
                                        N'-(2,3-dihydro-1,4-benzodioxin-6-ylmethylideneamino)-N-(2-hydroxyphenyl)octanediamide 0
                                        N'-(2-pyrrolylidenemethyl)-2,3-dihydro-1,4-benzodioxin-3-carbohydrazide 0
                                        N'-[(5-nitro-6-oxo-1-cyclohexa-2,4-dienylidene)methyl]-2,3-dihydro-1,4-benzodioxin-3-carbohydrazide 0
                                        N-(1,3-benzodioxol-5-ylmethylideneamino)-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                                        N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine 0
                                        N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-2-(6-methoxy-3-benzofuranyl)-N-methylacetamide 0
                                        N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-5,6-dimethyl-4-thieno[2,3-d]pyrimidinamine 0
                                        N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-5-ethyl-2-furancarboxamide 0
                                        N-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,5-dimethyl-4-pyrazolecarboxamide 0
                                        N-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-(2-pyrimidinyl)-3-piperidinecarboxamide 0
                                        N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(6-methoxy-1H-benzimidazol-2-yl)thio]acetamide 0
                                        N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[4-(2-furanylmethyl)-5-(phenoxymethyl)-1,2,4-triazol-3-yl]thio]acetamide 0
                                        N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-methoxy-4-propan-2-yloxybenzamide 0
                                        N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-morpholinecarboxamide 0
                                        N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5,7-dimethyl-3-pyrazolo[1,5-a]pyrimidinecarboxamide 0
                                        N-(3-chloro-2-pyridinyl)-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                                        N-(3-methyl-6-methylsulfonyl-1,3-benzothiazol-2-ylidene)-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                                        N-(4-bromo-1,3-benzothiazol-2-yl)-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                                        N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-oxo-3-pyrrolidinecarboxamide 0
                                        N-(6-bromo-2,3-dihydro-1,4-benzodioxin-7-yl)-2-furancarboxamide 0
                                        N-(6-chloro-2,3-dihydro-1,4-benzodioxin-7-yl)-3-phenylpropanamide 0
                                        N-(6-fluoro-1,3-benzothiazol-2-yl)-6,7-dihydro-[1,4]dioxino[2,3-f][1,3]benzothiazol-2-amine 0
                                        N-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-oxomethyl]-2-[[5-(2-methoxyanilino)-1,3,4-thiadiazol-2-yl]thio]acetamide 0
                                        N-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-sulfanylidenemethyl]-2,4-dimethylbenzamide 0
                                        N-[(2-chlorophenyl)methyl]-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-hydroxy-5-nitro-4-triazolimine 0
                                        N-[(2-methoxyphenyl)methyl]-N-methyl-2,3-dihydro-1,4-benzodioxin-3-carboxamide 0
                                        N-[(3-bromo-4-ethoxy-5-methoxyphenyl)methyl]-2,3-dihydro-1,4-benzodioxin-6-amine 0
                                        N-[(4,5-dibromo-2-furanyl)methylideneamino]-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                                        N-[(5-bromo-2-furanyl)methylideneamino]-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                                        N-[(6-chloro-1,3-benzodioxol-5-yl)methylideneamino]-2,3-dihydro-1,4-benzodioxin-6-carboxamide 0
                                        N-[1-[4-(4-methylphenyl)-2-thiazolyl]-4-piperidinyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide 0
                                        N-[2-(2-imidazo[1,2-a]pyridinyl)ethyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide 0
                                        N-[7-(1-oxopropyl)-2,3-dihydro-1,4-benzodioxin-6-yl]benzamide 0
                                        N-[[5-(2-nitrophenyl)-2-furanyl]methylideneamino]-2,3-dihydro-1,4-benzodioxin-3-carboxamide 0
                                        aiphanol 0
                                        doxazosin + 32
                                        eliglustat 1
                                        guabenxan 0
                                        guaimesal 0
                                        guanoxan 0
                                        idazoxan + 14
                                        lignin cw compound-3043 0
                                        lignin cw compound-3044 0
                                        lignin cw compound-3068 0
                                        lignin cw compound-3069 0
                                        lignin cw compound-3070 0
                                        silandrin 0
                                        silibinin 95
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.